Literature DB >> 11950952

Methods of molecular analysis: mutation detection in solid tumours.

I M Frayling1.   

Abstract

Most mutation detection techniques are unsuitable for routine use on solid tumours. Important parameters include sensitivity, specificity, efficiency, use of existing resources, and cost. In the UK, < 0.2% of service genetics laboratory activity involves mutation analysis in tumours (usually for family studies), mainly because it is time consuming/labour intensive (thus expensive) and DNA extracted from formalin fixed, paraffin wax embedded tissue is of low quality and yield. The small size of DNA fragments obtained from tissue blocks limits the polymerase chain reaction, the basis of most mutation detection methods. Other, biological, factors include: (1) heterogeneity of mutations within and between tumours, (2) variation in type and site of mutations in any one gene, (3) normal tissue harbouring mutations, (4) few genes are mutated in most of any one tumour type, and (5) few clinically useful correlations with genetic changes have been found. Present research is centred on correlating single gene mutations with various clinicopathological features, but the pattern of mutations in a combination of genes will probably prove more useful. Microsatellite instability, however, appears to be worth testing for in both familial and sporadic tumours, particularly of the colorectum.

Entities:  

Mesh:

Year:  2002        PMID: 11950952      PMCID: PMC1187151          DOI: 10.1136/mp.55.2.73

Source DB:  PubMed          Journal:  Mol Pathol        ISSN: 1366-8714


  35 in total

Review 1.  Laser micromanipulation systems as universal tools in cellular and molecular biology and in medicine.

Authors:  K Schütze; H Pösl; G Lahr
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  1998-07       Impact factor: 1.770

2.  Microsatellite instability is rare in rectal carcinomas and signifies hereditary cancer.

Authors:  M Nilbert; M Planck; E Fernebro; A Borg; A Johnson
Journal:  Eur J Cancer       Date:  1999-06       Impact factor: 9.162

3.  Detection of APC mutations in stool DNA of patients with colorectal cancer by HD-PCR.

Authors:  R Deuter; O Müller
Journal:  Hum Mutat       Date:  1998       Impact factor: 4.878

4.  Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy.

Authors:  A Hemminki; J P Mecklin; H Järvinen; L A Aaltonen; H Joensuu
Journal:  Gastroenterology       Date:  2000-10       Impact factor: 22.682

Review 5.  Nucleic acid-based methods for the detection of cancer.

Authors:  D Sidransky
Journal:  Science       Date:  1997-11-07       Impact factor: 47.728

Review 6.  Genetic prognostic markers in colorectal cancer.

Authors:  R S Houlston; I P Tomlinson
Journal:  Mol Pathol       Date:  1997-12

Review 7.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.

Authors:  C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

8.  Clinical findings with implications for genetic testing in families with clustering of colorectal cancer.

Authors:  J T Wijnen; H F Vasen; P M Khan; A H Zwinderman; H van der Klift; A Mulder; C Tops; P Møller; R Fodde
Journal:  N Engl J Med       Date:  1998-08-20       Impact factor: 91.245

9.  Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability.

Authors:  J M Cunningham; E R Christensen; D J Tester; C Y Kim; P C Roche; L J Burgart; S N Thibodeau
Journal:  Cancer Res       Date:  1998-08-01       Impact factor: 12.701

10.  Induction of microsatellite instability by oxidative DNA damage.

Authors:  A L Jackson; R Chen; L A Loeb
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

View more
  8 in total

Review 1.  Krüppel cripples prostate cancer: KLF6 progress and prospects.

Authors:  Goutham Narla; Scott L Friedman; John A Martignetti
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

Review 2.  Molecular prescreening to select patient population in early clinical trials.

Authors:  Jordi Rodón; Cristina Saura; Rodrigo Dienstmann; Ana Vivancos; Santiago Ramón y Cajal; José Baselga; Josep Tabernero
Journal:  Nat Rev Clin Oncol       Date:  2012-04-03       Impact factor: 66.675

3.  EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer.

Authors:  S Kamel-Reid; G Chong; D N Ionescu; A M Magliocco; A Spatz; M Tsao; X Weng; S Young; T Zhang; D Soulieres
Journal:  Curr Oncol       Date:  2012-04       Impact factor: 3.677

4.  KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer.

Authors:  Wilbur A Franklin; Jerry Haney; Michio Sugita; Lynne Bemis; Antonio Jimeno; Wells A Messersmith
Journal:  J Mol Diagn       Date:  2009-12-10       Impact factor: 5.568

5.  Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics.

Authors:  Vassiliki Kotoula; Elpida Charalambous; Bart Biesmans; Andigoni Malousi; Eleni Vrettou; George Fountzilas; George Karkavelas
Journal:  PLoS One       Date:  2009-11-04       Impact factor: 3.240

6.  KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies.

Authors:  D Soulières; W Greer; Anthony M Magliocco; D Huntsman; S Young; M-S Tsao; S Kamel-Reid
Journal:  Curr Oncol       Date:  2010-07       Impact factor: 3.677

7.  Intraspecies genotype variability of the microsporidian parasite Encephalitozoon hellem.

Authors:  María Haro; Carmen Del Aguila; Soledad Fenoy; Nuno Henriques-Gil
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

8.  Detection of rare point mutation via allele-specific amplification in emulsion PCR.

Authors:  Changming Cheng; Yin Zhou; Chao Yang; Juan Chen; Jie Wang; Jie Zhang; Guoping Zhao
Journal:  BMB Rep       Date:  2013-05       Impact factor: 4.778

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.